A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions

Inclusion Criteria (applicable to all participants and all parts unless otherwise specified): * Have given informed consent by signing and dating the informed consent form (ICF) before initiation of any trial-specific procedures. * Are aged 18 to 55 years, have a body mass index over 18.5 kg/m\^2 and under 35 kg/m\^2 and weigh at least 50 kg at Visit 0. * Are willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the trial. This includes that they are able to understand and follow trial-related instructions. * Are overall healthy in the clinical judgment of the investigator based on medical history, physical examination, 12-lead electrocardiogram (ECG), vital signs, and screening laboratory tests (blood clinical laboratory) at Visit 0 (for Part C only: (all results must be available prior to Pre-dose Visit 1). * Part C only: Have had * a diagnosis (\>1 year) of genital herpes confirmed in medical records; and * with at least 3 and no more than 9 participant-reported genital herpes recurrences either in the 1 year preceding Visit 0, or, if currently on continuous antiviral therapy, in the 1 year preceding the start of continuous antiviral therapy. * Part C only: Are seropositive for HSV-2 as determined by Western Blot (result must be available prior to Pre-Dose Visit 2). * Part C only: Are willing to comply with the protocol-specified schedule for continuous antiviral therapy. * Part C only: Are willing to refrai…